Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 26 Oct 2022 |
| ORION CORPORATION: ACQUISITION OF OWN SHARES 26.10.2022 | 26 Oct 2022 |
| Orion Corporation: Acquisition of Own Shares 25.10.2022 | 25 Oct 2022 |
| Orion Corporation: Acquisition of Own Shares 24.10.2022 | 24 Oct 2022 |
| Orion Corporation: Acquisition of Own Shares 21.10.2022 | 21 Oct 2022 |